Literature DB >> 29247305

Neurologic disease in feline immunodeficiency virus infection: disease mechanisms and therapeutic interventions for NeuroAIDS.

Christopher Power1.   

Abstract

Feline immunodeficiency virus (FIV) is a lentivirus that causes immunosuppression through virus-mediated CD4+ T cell depletion in feline species. FIV infection is complicated by virus-induced disease in the nervous system. FIV enters the brain soon after primary infection and is detected as FIV-encoded RNA, DNA, and proteins in microglia, macrophages, and astrocytes. FIV infection activates neuroinflammatory pathways including cytokines, chemokines, proteases, and ROS with accompanying neuronal injury and loss. Neurobehavioral deficits during FIV infection are manifested as impaired motor and cognitive functions. Several treatment strategies have emerged from studies of FIV neuropathogenesis including the therapeutic benefits of antiretroviral therapies, other protease inhibitors, anti-inflammatory, and neurotrophic compounds. Recently, insulin's antiviral, anti-inflammatory, and neuroprotective effects were investigated in models of lentivirus brain infection. Insulin suppressed HIV-1 replication in human microglia as well as FIV replication of lymphocytes. Insulin treatment diminished cytokine and chemokine activation in HIV-infected microglia while also protecting neurons from HIV-1 Vpr protein-mediated neurotoxicity. Intranasal (IN) insulin delivery for 6 weeks suppressed FIV expression in the brains of treated cats. IN insulin also reduced neuroinflammation and protected neurons in the hippocampus, striatum, and neocortex of FIV-infected animals. These morphological and molecular effects of IN insulin were confirmed by neurobehavioral studies that showed IN insulin-treated FIV-infected animals displayed improved motor and cognitive performance compared to sham-treated FIV-infected animals. Thus, FIV infection of the nervous system provides a valuable comparative in vivo model for discovering and evaluating disease mechanisms as well as developing therapeutic strategies for NeuroAIDS in humans.

Entities:  

Keywords:  Antiretroviral therapy; FIV; HIV; Insulin; Neuroinflammation

Mesh:

Substances:

Year:  2017        PMID: 29247305     DOI: 10.1007/s13365-017-0593-1

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  75 in total

1.  Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity.

Authors:  Jacqueline A Pettersen; Gareth Jones; Catherine Worthington; Hartmut B Krentz; Oliver T Keppler; Ahmet Hoke; M John Gill; Christopher Power
Journal:  Ann Neurol       Date:  2006-05       Impact factor: 10.422

2.  In vivo infection of ramified microglia from adult cat central nervous system by feline immunodeficiency virus.

Authors:  A Hein; J P Martin; F Koehren; A Bingen; R Dörries
Journal:  Virology       Date:  2000-03-15       Impact factor: 3.616

3.  Cortical neuronal cytoskeletal changes associated with FIV infection.

Authors:  S Jacobson; S J Henriksen; O Prospero-Garcia; T R Phillips; J H Elder; W G Young; F E Bloom; H S Fox
Journal:  J Neurovirol       Date:  1997-08       Impact factor: 2.643

4.  Tumor necrosis factor-alpha and virus expression in the central nervous system of cats infected with feline immunodeficiency virus.

Authors:  A Poli; M Pistello; M A Carli; F Abramo; G Mancuso; E Nicoletti; M Bendinelli
Journal:  J Neurovirol       Date:  1999-10       Impact factor: 2.643

5.  Proteinase-activated receptor-1 mediates dorsal root ganglion neuronal degeneration in HIV/AIDS.

Authors:  Shaona Acharjee; Yu Zhu; Ferdinand Maingat; Carlos Pardo; Klaus Ballanyi; Morley D Hollenberg; Christopher Power
Journal:  Brain       Date:  2011-10-21       Impact factor: 13.501

6.  Detection of feline immunodeficiency proviral sequences in lymphoid tissues and the central nervous system by in situ gene amplification.

Authors:  S Macchi; F Maggi; C Di Iorio; A Poli; M Bendinelli; M Pistello
Journal:  J Virol Methods       Date:  1998-07       Impact factor: 2.014

7.  Productive infection of human peripheral blood mononuclear cells by feline immunodeficiency virus: implications for vector development.

Authors:  J Johnston; C Power
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

8.  Neurological abnormalities associated with feline immunodeficiency virus infection.

Authors:  T R Phillips; O Prospero-Garcia; D L Puaoi; D L Lerner; H S Fox; R A Olmsted; F E Bloom; S J Henriksen; J H Elder
Journal:  J Gen Virol       Date:  1994-05       Impact factor: 3.891

Review 9.  Restrictions to cross-species transmission of lentiviral infection gleaned from studies of FIV.

Authors:  Sue VandeWoude; Jennifer Troyer; Mary Poss
Journal:  Vet Immunol Immunopathol       Date:  2009-10-14       Impact factor: 2.046

10.  Neurovirulence in feline immunodeficiency virus-infected neonatal cats is viral strain specific and dependent on systemic immune suppression.

Authors:  C Power; R Buist; J B Johnston; M R Del Bigio; W Ni; M R Dawood; J Peeling
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

View more
  4 in total

Review 1.  Current and Future Therapeutic Strategies for Lentiviral Eradication from Macrophage Reservoirs.

Authors:  Tiffany A Peterson; Andrew G MacLean
Journal:  J Neuroimmune Pharmacol       Date:  2018-10-13       Impact factor: 4.147

2.  Optimizing animal models for HIV-associated CNS dysfunction and CNS reservoir research.

Authors:  Jeymohan Joseph
Journal:  J Neurovirol       Date:  2018-03-26       Impact factor: 2.643

3.  Potential Causes of Increased Vocalisation in Elderly Cats with Cognitive Dysfunction Syndrome as Assessed by Their Owners.

Authors:  Petra Černá; Hannah Gardiner; Lorena Sordo; Camilla Tørnqvist-Johnsen; Danièlle A Gunn-Moore
Journal:  Animals (Basel)       Date:  2020-06-24       Impact factor: 2.752

Review 4.  HIV Associated Neurodegenerative Disorders: A New Perspective on the Role of Lipid Rafts in Gp120-Mediated Neurotoxicity.

Authors:  Lisa K Smith; Thomas B Kuhn; Jack Chen; James R Bamburg
Journal:  Curr HIV Res       Date:  2018       Impact factor: 1.581

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.